Day: May 8, 2024

RIMOUSKI, Quebec, May 08, 2024 (GLOBE NEWSWIRE) — Puma Exploration Inc. (TSXV: PUMA, OTCQB: PUMXF) (the “Company” or “Puma”) is pleased to launch its 2024 exploration program at its 100%-owned Jonpol Gold property located 8 km east of its Williams Brook property in Northern New Brunswick. As outlined in its News Release of January 17, 2024, Puma is expanding its regional exploration fieldwork to prospective areas of the Williams Brook Project to identify additional priority targets and add to the Williams Brook gold inventory. A focused exploration program will be deployed this summer at the Jonpol Gold property and its new expansion (see Figure 1) to advance the Company’s understanding of the sizeable orogenic gold system at play in the region and identify additional potential gold deposits. Figure 1. Williams...

Equinor Commits to Contribute up to a US$160 million Gross Investment for a 45% interest in two special purpose entities with SLI to develop a sustainable lithium business in the United States VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today announced the closing of a landmark strategic partnership (the “Transaction”) with Equinor ASA (NYSE: EQNR), a multinational energy company and recognized leader in renewables and low-carbon solutions, to accelerate the development of Standard Lithium’s large-scale, sustainable lithium projects in the Smackover Formation. The Transaction includes Equinor’s contribution of up to US$160 million, representing its total...

CORONA, Calif., May 08, 2024 (GLOBE NEWSWIRE) — Monster Beverage Corporation (NASDAQ: MNST) today announced that it has commenced a modified “Dutch auction” tender offer to purchase shares of its common stock for cash at a price per share of not less than $53.00 and not greater than $60.00, for a maximum aggregate purchase price of up to $3.0 billion. The tender offer begins today, May 8, 2024, and will expire at 11:59 p.m., New York City time, on June 5, 2024, unless extended or earlier terminated by Monster. The tender offer will be funded using a combination of (1) $2.0 billion of cash on hand, (2) $750.0 million in borrowings under a new term loan, and (3) $250.0 million in borrowings under a new revolving credit facility. Monster and certain of its subsidiaries expect to enter into a new credit agreement providing for a new...

Expanded Activities Position Rakovina Therapeutics to Capitalize on AI Partnerships with The University of British Columbia and Pharma Inventor Inc. VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the expansion of two research collaborations to align with its recently announced collaboration with the Deep Docking AI Drug Discovery Platform. On March 27, 2024, the Company announced an agreement granting Rakovina Therapeutics exclusive access to the proprietary Deep Docking AI platform for DNA-damage response targets. Using the Deep Docking AI platform, the Company is analyzing billions of molecular...

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2024 financial results and provide an update on its business and pipeline on Wednesday, May 15, after the market close. The Company does not intend to host a conference call, and anticipates resuming quarterly earnings calls at the time it announces second quarter 2024 results. About Spero Therapeutics Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug...

COLUMBUS, Ohio, May 08, 2024 (GLOBE NEWSWIRE) — Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico today announced that David Duvall, President and CEO, and John Zimmer, EVP and CFO, will participate in the EF Hutton Annual Global Conference at The Plaza Hotel in New York City on May 15, 2024. Investors interested in arranging a one-on-one meeting should contact your conference representative or the Company’s investor relations contacts listed below. About Core Molding Technologies, Inc. Core Molding Technologies is a leading engineered materials...

The U.S. medical scientific community is calling for clinical studies to expand shared understanding of babesiosis, an emerging tick-borne illness. The upcoming 60 Degrees Pharma clinical trial of tafenoquine in treating babesiosis will be the first and only such study to date. Enrollment is planned to begin in summer 2024. The Journal of Infectious Diseases has published a letter outlining the planned trial protocol.WASHINGTON, May 08, 2024 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that a letter, titled Trial Planned to Evaluate Safety and Efficacy of Tafenoquine + Atovaquone/Azithromycin in Hospitalized Babesiosis Patients, authored by the Company’s Chief Executive Officer,...

Generated Significant 37% Year-over-Year Revenue Growth in Q1 2024 Recorded Positive Quarterly Net Income for Second Consecutive Quarter, and Positive Adjusted EBITDA and Cash Flow from Operations for Third Consecutive Quarter Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, May 08, 2024 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported first quarter 2024 financial results and provided an operational update. Recent Financial and Operational HighlightsFor the three months ended March 31, 2024, revenues were $9.1 million, a 37% increase as compared to the first quarter of 2023. Gross margin for the first quarter of 2024 was 75%, an increase from 73% in the first quarter...